The growth of Viagra and its effect on the pharmaceutical landscape presents a complex question for shareholders. While the first sales data were astounding, the intellectual property has lapsed, leading to a deluge of copycat alternatives that are chipping away at profit. In addition, the industry is facing challenges related to population tren… Read More